Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation.
Horm Metab Res · 2010
Last updated 2026-05-28In lab tests, the drug exendin-4 (a GLP-1 analogue) protected pancreatic beta cells from damage caused by the immunosuppressant rapamycin. When cells were exposed to rapamycin for 12 hours, about half died, but adding exendin-4 at the same dose prevented this cell death. Exendin-4 worked by blocking the activation of proteins called JNK and p38, which rapamycin normally triggers.
AI summary of the abstract below.
| Journal | Horm Metab Res, 2010 |
|---|---|
| Citations | 21 |
| Relative citation ratio | 0.57 |
| NIH percentile | 33 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
It has been reported that the immunosuppressant rapamycin decreases the viability of pancreatic beta cells. In contrast, exendin-4, an analogue of glucagon-like peptide-1, has been found to inhibit beta cell death and to increase beta cell mass. We investigated the effects of exendin-4 on the cytotoxic effect of rapamycin in beta cells. Incubation with 10 nM rapamycin induced cell death in 12 h in murine beta cell line MIN6 cells and Wistar rat islets, but not when coincubated with 10 nM exendin-4. Rapamycin was found to increase phosphorylation of c-Jun amino-terminal kinase (JNK) and p38 in 30 minutes in MIN6 cells and Wistar rat islets while exendin-4 decreased their phosphorylation. Akt and extracellular signal-regulated kinase (ERK) were not involved in the cytoprotective effect of exendin-4. These results indicate that exendin-4 may exert its protective effect against rapamycin-induced cell death in pancreatic beta cells by inhibiting JNK and p38 signaling.
Verbatim abstract via PubMed 20213584 ↗